Real Life Clinical Management and Survival in Advanced Cutaneous Melanoma: The Italian Clinical National Melanoma Registry Experience: Frontiers in Oncology

A. Crispo, M.T. Corradin, E. Giulioni, A. Vecchiato, P. Del Fiore, P. Queirolo, F. Spagnolo, V. Vanella, C. Caracò, G. Tosti, E. Pennacchioli, G. Giudice, E. Nacchiero, P. Quaglino, S. Ribero, M. Giordano, D. Marussi, S. Barruscotti, M. Guida, V. De GiorgiM. Occelli, F. Grosso, G. Cairo, A. Gatti, D. Massa, L. Atzori, N. Calvani, T. Fabrizio, G. Mastrangelo, F. Toffolutti, E. Celentano, M. Budroni, S. Gandini, C.R. Rossi, A. Testori, G. Palmieri, P.A. Ascierto, the Clinical National Melanoma Registry Study Group at the Italian Melanoma Intergroup

Research output: Contribution to journalArticlepeer-review

Abstract

Background: Cutaneous melanoma (CM) is one of the most aggressive types of skin cancer. Currently, innovative approaches such as target therapies and immunotherapies have been introduced in clinical practice. Data of clinical trials and real life studies that evaluate the outcomes of these therapeutic associations are necessary to establish their clinical utility. The aim of this study is to investigate the types of oncological treatments employed in the real-life clinical management of patients with advanced CM in several Italian centers, which are part of the Clinical National Melanoma Registry (CNMR). Methods: Melanoma-specific survival and overall survival were calculated. Multivariate Cox regression models were used to estimate the hazard ratios adjusting for confounders and other prognostic factors. Results: The median follow-up time was 36 months (range 1.2-185.1). 787 CM were included in the analysis with completed information about therapies. All types of immunotherapy showed a significant improved survival compared with all other therapies (p=0.001). 75% was the highest reduction of death reached by anti-PD-1 (HR=0.25), globally immunotherapy was significantly associated with improved survival, either for anti-CTLA4 monotherapy or combined with anti-PD-1 (HR=0.47 and 0.26, respectively) and BRAFI+MEKI (HR=0.62). Conclusions: The nivolumab/pembrolizumab in combination of ipilimumab and the addition of ant-MEK to the BRAFi can be considered the best therapies to improve survival in a real-world-population. The CNMR can complement clinical registries with the intent of improving cancer management and standardizing cancer treatment. © Copyright © 2021 Crispo, Corradin, Giulioni, Vecchiato, Del Fiore, Queirolo, Spagnolo, Vanella, Caracò, Tosti, Pennacchioli, Giudice, Nacchiero, Quaglino, Ribero, Giordano, Marussi, Barruscotti, Guida, De Giorgi, Occelli, Grosso, Cairo, Gatti, Massa, Atzori, Calvani, Fabrizio, Mastrangelo, Toffolutti, Celentano, Budroni, Gandini, Rossi, Testori, Palmieri, Ascierto and the Clinical National Melanoma Registry Study Group at the Italian Melanoma Intergroup.
Original languageEnglish
JournalFront. Oncol.
Volume11
DOIs
Publication statusPublished - 2021

Keywords

  • cutaneous melanoma
  • immunotherapy
  • ipilimumab
  • medical record systems
  • survival analysis
  • cobimetinib
  • dabrafenib
  • lactate dehydrogenase
  • nivolumab
  • pembrolizumab
  • trametinib
  • vemurafenib
  • adult
  • advanced cancer
  • Article
  • cancer prognosis
  • cancer radiotherapy
  • cancer staging
  • cancer survival
  • cohort analysis
  • controlled study
  • disease free survival
  • ECOG Performance Status
  • electrochemotherapy
  • female
  • follow up
  • gene mutation
  • histology
  • human
  • major clinical study
  • male
  • middle aged
  • molecularly targeted therapy
  • mortality risk
  • overall survival
  • questionnaire
  • retrospective study

Fingerprint

Dive into the research topics of 'Real Life Clinical Management and Survival in Advanced Cutaneous Melanoma: The Italian Clinical National Melanoma Registry Experience: Frontiers in Oncology'. Together they form a unique fingerprint.

Cite this